Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree a trip to China costs peanuts...
Doog- I agree with your numbers.
Big wild card in play. I really think China = IPCI Generic Pipeline Manufacturing. China always is manufacturing... Lets hope those plants are FDA approved and up and running soon. Then we might see commercialization of Gluco and Keppra. As well as Seroquel manufacturing going to China. Then as the pipeline gains more and more approvals, all manufacturing will take place in China.
https://www.cbsnews.com/news/spacex-falcon-heavy-launch-spectacular-maiden-flight/
I do not care for Elon Musk but I have to admit he certainly does deliver what he says he will. he can also raise money at the drop of a hat and not put the screws to his current shareholders. Dr. Odidi could learn a lot by taking a long hard look in the mirror and comparing himself to Elon Musk. I would have to say those two individuals are polar opposites:
Odidi- keeps progress/goals at a snails pace while trying to save money and micro managing... But set backs are the norm and progress is minimal. And each and every offering is at a lower level that puts the screws to past shareholders who have supported him.
Musk- has huge goals/ambitions and finds the best people to delegate authority to and delivers lots of progress. And when he needs to raise money, he does at a level that does not dilute out past shareholders. He also often invests some of his money at these offerings as well.
Mopar- If what these guys allege is going on... People are going to see the inside of a jail cell along with being sued from every angle imaginable.
Jack- Absolutely nothing wrong with being CEO of another company... Or owning an interest in another company in the same competitive space. The problem arises when you do not disclose said relationship. For Odidi to be CEO of another company or own a stake in another company operating in the same competitive space as IPCI... As CEO of IPCI, I would say that is certainly material information and he would be required to disclose. I cannot believe for a second he would not disclose. Nobody is that stupid. So I am guessing when all the details emerge on Smart Pharma it all will make sense.
Here is my take on earnings and conference call:
1. 4Q revenue will be disappointing. About $1M for Focalin and not much for Seroquel. Total revenue will be about $1-1.5M.
2. They just gave a very comprehensive update. I do not expect much more info in report/conference call other than to maybe clarify some of the items in the update.
3. It sounds like the Chinese deal is not complete yet. I expect very little additional info on this unless the deal is complete. However, I expect the deal not to be complete by earnings.
Blue- 100% agreed. Something like that might even be seen as criminal as well. Jack is just working on covering right now. This is how they work it:
Pumping = selling
Bashing = covering
Sprot- US patents are no good in China. Lots of Chinese companies steal technology from US and it is totally legal. The only caveat is they have a hard time selling the products in markets that recognize US patents.
Sprot- What questions do you have for management at CC?
Doog and Sprot- The only thing good about earnings will be YOY revenue shows growth. Unfortunately I think Seroquel revenues are going to be real low. Focalin XR total revenues for 2018 should be about $5M. It is unclear at this point what Seroquel XR revenues will be for 2018. I look forward to the conference call for clarification on many items. A couple of questions I have:
1. Please elaborate on the latest Chinese deal that is in process?
2. What is Dr Odidi's relationship to the Smart Pharma entity? Is Dr. Odidi one of the owners of Smart Pharma? Did Dr. Odidi found Smart Pharma?
3. What is expected 2018 revenue for Seroquel XR?
Lets hear some more questions.
Tilator- If Odidi needs to micro manage every business decision why do you need to have a VP drawing 6 figures with nothing to do? You don't...
Tilator- Sales of what? They do not sell or market their own products at this point? The only partnership they have entered in is MNK... I mean really, how can that position be justified at all?
Tilator- 100% right. They need an experienced person to handle all regulatory agency/FDA applications, issues, etc. Get rid of Akempyon and hire someone to deal with FDA. I mean, really, what has Akempyon done in the last couple years? There has been no new business development... Here is his description on IPCI website:
Christian Akyempon, B.Sc. (Honors), M.Sc., MBA
Vice President, Commercial Operations
Christian Akyempon is currently the Vice President, Commercial Operations, at Intellipharmaceutics Corp. In this role, Mr. Akyempon oversees the strategic functions of Marketing, Sales and Business Development. Prior to assuming this role, he worked as the VP, Business Development for Global Pharma Partners with responsibilities for the Canadian market. Before then, he was the Director of Business Development and Government Affairs at Taro Canada until May 2013. His extensive career with both generic and brand pharmaceutical firms include several managerial roles in Business Development, Marketing and Sales at Teva Canada, ratiopharm, GlaxoSmithKline and Sterling Winthrop. At Teva, he played a pivotal role in the integration of ratiopharm into Teva Canada. Over a seven-year period, Mr. Akyempon also provided strategic business solutions and market audits to pharma firms specializing in Diagnostic Imaging in the hospital environment through Medimark Consultants.
Christian holds an MBA from the University of Ottawa, a M.Sc. in Pharmaceutical Sciences from the University of British Columbia, and an Honors B.Sc. from the University of Waterloo.
Tilator- Part of the problem with IPCI is their FDA applications are not good enough... Look at Rexista, they submitted without doing the nasal and oral HAP studies. Seems like an incomplete application to me. Now that info along with the years of delays, I can draw a conclusion on why so many ANDAs have been held up. In my opinion, applications were insufficient.
Tilator- Whatever happened with you trying to buy some Glucho?
Fabius- I get the feeling the next thing we hear about Seroquel is that it cannot be manufactured cost competitively in Toronto. Thus, production in China. Just a guess on my part though...
Fred- I think the Chinese deal could also involve manufacturing generics for sale in US. Seroquel, Keppra, Gluco, Lamictal, Pristiq. People manufacture in China to get lower cost of goods. That is what I feel the major intent is here. Have them manufacture generics for all markets. A small shop in Toronto is not a good fit for manufacturing high volume, cost sensitive generic pharmaceuticals.
Fred- I thought last offering contingency said they could not sell ATM shares for 6 months after. But I do not disagree with you a Wainright upgrade usually means they are trying to broker an offering... I would like to hear your opinion on the China news.
Samsa- That is exactly what they did. They covered because they got wind of the china thing. Then propped it up for a day or two and sold short into the little rally. Then they walked it down. It is one of the MM's who does this.
Mopar- yep...
I hope all the complainers tune in to the conference call and ask the relevant questions. I can just see afterwards, all the complaining about nobody asked this or nobody asked that. If you have a question, tune in and ask. No excuses!
Agreed Doog. Revenues definitely are growing. Will be interesting to see where they are at this quarter. The impression I get is that Seroquel revenue was pretty much nil last quarter. So lets hope for the best and hope my estimates are on the low side!
Sprot- You mentioned next earnings things becoming clear. 2017Q4 earnings for IPCI will be about $1-1.5M in my opinion. Some people are hoping they can crack $2M but I don't think they quite get there. I am certainly hoping they do and believe there is an outside chance of this. But me personally... I will be happy if they can hit $1.5M. I just don't get the feeling Seroquel XR sales are really going anywhere yet. Thus, I feel $1M roughly for Focalin XR and whatever they can scrape up on Seroquel will put them between $1-1.5M.
Thanks for posting Mopar and I agree with what you said. China is about manufacturing. And if you just envision in your mind what makes sense, everything becomes clear. IPCI is partnering up with a Chinese manufacturer. In my opinion this manufacturer will be supplying most of their generics.
Yep have a great weekend. 2018 looks promising.
They are doing whatever they can to keep the price down. They keep throwing small ask lots around. Multiple sales of 1 share, 39 shares, 100 shares. That is how they keep the price where they want it. They rarely touch the real orders though and just wash trade above those.
Tilator- You and me are on the same page. When I saw the word China I knew that meant Gluco and Keppra... As well as all the other drugs too.
Doog- I do think people may be overthinking this China news. China is all about manufacturing. Also, they just don't let citizens from other countries set up manufacturing on a whim. What I think is going on is Odidi is going down the proper avenues to do this successfully. But bottom line it is all about manufacturing.
Doog- You hit the nail on the head. As long as the deals have the best interest of IPCI shareholders in mind, I see no issues. Business is all about strategic partnerships that help companies grow their markets and revenues. What I see here is IPCI doing just that. Once all the details are worked out we will hear more.
I also think Mopar has pointed out that business' in China might have different things they need to conform too.
The advantages of this Chinese opportunity are many:
1. Ability to produce lower cost drugs.
2. New markets.
3. Increased manufacturing throughput.
Numbers- yes you are right. A number of people have pointed this out but everyone did not catch on yet.
wimike- I don't think it will drop. As I am guessing they commenced short selling again yesterday and are again now taking a short position. I think it all depends on how they feel earnings will be interpreted and the possibility of an ANDA approval soon.
wimike- I think that volume last Friday was the MM just churning back and forth to himself while he covered his short. News had already leaked on the China plant and he wasn't going to take any chances getting caught short.
Very good update!
Doog- 100% agreed. It is taking so long the shorts will have a field day turning whatever this is into something negative.
Doog- IPCI likes to keep some terms of deals private. People are not going to like that going forward in terms to an agreement Odidi makes with himself.
Doog- I agree, I don't think Odidi is up to no good. But by not disclosing these arrangements he "appears" to be hiding something.
Angelo- If there is a conflict of interest, I am 100% on board with going after them.
Doog- I will agree with you that the scenario you outline is not illegal. However, if Odidi is CEO of both companies and sole or high % owner of Smart. He must use absolute transparency in all negotiations between IPCI and Smart. If he does not, he is going to run into a problem where litigation results as people feel it is a conflict of interest.
Angelo- I agree with you 100%. How does the CEO of IPCI- a publicly traded company that has issues- have the time to open another company and become CSO and CEO of that as well... Oh and by the way, that company will profit on all the approvals/IP IPCI shareholders have paid for over the years... But said CEO will reap 100% of the profits off that entity. Now no one could actually be that stupid- right?
Nasdaq2020 - read articles and look at photos. The backdrop lists all relevant companies and ipci is listed